Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1A46 in Relapsed/Refractory CD20/CD19-Positive B-Cell NHL
ChiCTR2300075049Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 1A46 in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 5 more, sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Safety and tolerability of 1A46 (Phase I) and Optimal overall response rate (ORR) (Phase II). Started Aug 2023; status: recruiting.
02
Drugs
1A46
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on ChiCTR2300075049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075049.